PE20170184A1 - Derivados de piperidina como antagonista de receptores de orexina - Google Patents

Derivados de piperidina como antagonista de receptores de orexina

Info

Publication number
PE20170184A1
PE20170184A1 PE2016001578A PE2016001578A PE20170184A1 PE 20170184 A1 PE20170184 A1 PE 20170184A1 PE 2016001578 A PE2016001578 A PE 2016001578A PE 2016001578 A PE2016001578 A PE 2016001578A PE 20170184 A1 PE20170184 A1 PE 20170184A1
Authority
PE
Peru
Prior art keywords
optionally substituted
substituted
orexin receptors
antagonist
compounds
Prior art date
Application number
PE2016001578A
Other languages
English (en)
Inventor
Shuhui Chen
Yuan Chen
Haiying He
Jiong Lan
Yang Zhang
Qiang Lv
Biao Ma
Yuhe Wang
Songliang Wu
Xing Liu
Original Assignee
Shanghai Haiyan Pharmaceutical Tech Co Ltd
Yangtze River Pharm Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54054589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Haiyan Pharmaceutical Tech Co Ltd, Yangtze River Pharm Group Co filed Critical Shanghai Haiyan Pharmaceutical Tech Co Ltd
Publication of PE20170184A1 publication Critical patent/PE20170184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA (I) DONDE A ES UN CICLOHIDROCARBILO, HETEROCICLOHIDROCARBILO O HETEROHIDROCARBILO CICLICO DE 3 A 12 MIEMBROS OPCIONALMENTE SUSTITUIDO; B ES C(=O), S(=O) O S(=O)2; X ES (CH2)r1(U)r2(CH2)r3 OPCIONALMENTE SUSTITUIDO, EN DONDE U ES HALOGENO, HIDROXI, ALQUILO C1-6, ENTRE OTROS; D Y L SON CADA UNO CH2 OPCIONALMENTE SUSTITUIDO CON F, Br, CN, ENTRE OTROS; T ES C O UN ENLACE; CUANDO M ES C(Y)(R1a) Q ES C(R1b)(R1c) Y VICEVERSA, EN DONDE Y ES (CH2)r4(G)r5(CH2)r6-Y1; Y1 es O-E, ENTRE OTROS, EN DONDE E ES CICLOHIDROCARBILO O HETEROCICLO DE 5 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; G ES HALOGENO SUSTITUIDO, HIDROXI SUSTITUIDO, ENTRE OTROS; r1, r3, r4 y r6 SON DE 0 A 2; r2 y r5 SON 0 O 1; R1a, R1b, R1c, R2 y R3 SON CADA UNO H, F, CN, NH2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE RECEPTORES DE OREXINA SIENDO UTILES EN EL TRATAMIENTO DE INSOMNIO, ANSIEDAD, TRASTORNO OBSESIVO-COMPULSIVO
PE2016001578A 2014-03-06 2015-02-27 Derivados de piperidina como antagonista de receptores de orexina PE20170184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410081220 2014-03-06

Publications (1)

Publication Number Publication Date
PE20170184A1 true PE20170184A1 (es) 2017-04-07

Family

ID=54054589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001578A PE20170184A1 (es) 2014-03-06 2015-02-27 Derivados de piperidina como antagonista de receptores de orexina

Country Status (16)

Country Link
US (1) US10100047B2 (es)
EP (1) EP3115362B1 (es)
JP (1) JP6262885B2 (es)
KR (1) KR101920472B1 (es)
CN (1) CN106414439B (es)
AU (1) AU2015226679B2 (es)
CA (1) CA2941663C (es)
CL (1) CL2016002240A1 (es)
IL (1) IL247584A0 (es)
MX (1) MX2016011549A (es)
NZ (1) NZ723671A (es)
PE (1) PE20170184A1 (es)
RU (1) RU2669701C2 (es)
SG (2) SG10201900536TA (es)
WO (1) WO2015131773A1 (es)
ZA (1) ZA201606141B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008721A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AU2016295693B2 (en) 2015-07-17 2020-05-21 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
CN107709318B (zh) 2015-08-14 2020-09-25 上海海雁医药科技有限公司 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型
CA3005918C (en) 2015-11-23 2023-10-17 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
ES2907373T3 (es) 2016-02-04 2022-04-25 Takeda Pharmaceuticals Co Compuesto de piperidina sustituida y uso de la misma
CN115379830A (zh) * 2020-04-17 2022-11-22 上海海雁医药科技有限公司 固体药物制剂及其制备方法和用途
CN112480107B (zh) * 2020-11-30 2022-08-16 上海海雁医药科技有限公司 取代的氮杂双环辛烷化合物及其中间体和制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368457B2 (en) * 2003-05-13 2008-05-06 Schering Corporation Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors
WO2008024284A2 (en) * 2006-08-21 2008-02-28 Merck & Co., Inc. Sulfonylated piperazines as cannabinoid-1 receptor modulators
EP2150114A4 (en) * 2007-05-18 2012-01-18 Merck Sharp & Dohme OXO-BRIDGED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
EP2150115B1 (en) * 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
RU2470021C2 (ru) * 2007-05-23 2012-12-20 Мерк Шарп Энд Домэ Корп. Пиридилпиперидиновые антагонисты рецептора орексинов
US8188280B2 (en) * 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
RU2010138640A (ru) * 2008-02-21 2012-03-27 Актелион Фармасьютиклз Лтд (Ch) Производные 2-аза-бицикло [2.2.1] гептана
AU2009307918A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
JP2012506375A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
EP2350061B1 (en) * 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
EP2350066B1 (en) * 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2563780B1 (en) * 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
ES2823350T3 (es) * 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
TW201315730A (zh) * 2011-07-05 2013-04-16 大正製藥股份有限公司 甲基哌啶衍生物
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
JP6099051B2 (ja) * 2011-10-25 2017-03-22 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するへテロ環誘導体
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
WO2014075392A1 (en) 2012-11-16 2014-05-22 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途

Also Published As

Publication number Publication date
EP3115362A4 (en) 2017-08-16
MX2016011549A (es) 2017-05-08
KR20160143668A (ko) 2016-12-14
EP3115362B1 (en) 2019-06-12
RU2669701C2 (ru) 2018-10-15
CN106414439A (zh) 2017-02-15
CA2941663C (en) 2020-02-18
CN106414439B (zh) 2017-12-08
KR101920472B1 (ko) 2019-02-08
AU2015226679A1 (en) 2016-09-15
US10100047B2 (en) 2018-10-16
RU2016130937A (ru) 2018-04-09
SG10201900536TA (en) 2019-02-27
NZ723671A (en) 2017-05-26
US20170233385A1 (en) 2017-08-17
ZA201606141B (en) 2017-05-31
CA2941663A1 (en) 2015-09-11
AU2015226679B2 (en) 2017-05-25
JP2017507185A (ja) 2017-03-16
CL2016002240A1 (es) 2017-02-17
JP6262885B2 (ja) 2018-01-17
WO2015131773A1 (zh) 2015-09-11
EP3115362A1 (en) 2017-01-11
SG11201607183PA (en) 2016-10-28
IL247584A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
PE20170184A1 (es) Derivados de piperidina como antagonista de receptores de orexina
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
PE20160431A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CL2017002452A1 (es) Nuevos compuestos bicíclicos
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
PE20171306A1 (es) Derivados de quinazolina utilizados para tratar el vih
AR099677A1 (es) Compuesto heterocíclico fusionado y su uso para el control de plagas
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
CL2015002609A1 (es) 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.
EA201590092A1 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
PE20170144A1 (es) 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet
PE20161572A1 (es) Compuestos como moduladores de ror gamma
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
PE20120010A1 (es) Cefalosporinas que tienen un grupo catecol
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
PH12016501699A1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c&#39;] dipyrrol-2-yl
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20170295A1 (es) Compuestos de imidazopiridazina

Legal Events

Date Code Title Description
FD Application declared void or lapsed